21/04/2017 12:20:00

Participate in our $3 million Private Placement to Earn a Potential 20% Return on Investment in THC Therapeutics (THCT) Stock

LAS VEGAS, April 21, 2017 (GLOBE NEWSWIRE) -- THC Therapeutics (THCT) is offering a Reg D private placement to accredited investors, through which we will raise up to $3,000,000. Proceeds from this offering will start the process for THC Therapeutics to become a fully reporting company to the SEC. 50% of the money raised will go towards mergers and acquisitions, the other half will go toward general business operating expenses. This offering will be good for our company, current shareholders and new investors. An example of the terms is as follows, for a $100,000 investment in this private placement, the investor will receive $120,000 of common stock 1 year from the date of investment. The price per share will be determined by the market value at the time the common stock will be issued. This correlates to a 20% return on investment. Minimum investment is $25,000. Prior to investing, all investors must verify their accredited status. No offering is made to any person who does not meet the definition of an accredited investor under Rule 501(a). Further information is contained in our private placement memorandum, which should be reviewed in full before making a decision to invest.

Visit our website to participate in THC Therapeutics Private Placement. (http://thctherapeutics.com/)

Comments from Brandon Romanek, Founder & CEO, “Because of my vast experience as a trader, investor and portfolio manager, I have come up with a creative strategy where one can make a potential 20% return on investment. This will be great for THC Therapeutics, our current shareholders and investors in this offering. I am not willing to sell shares at a discount in an offering like this anywhere near our current stock price. Most of these types of offerings are priced below market value. Investors would have to hold for one year and this could present substantial risk to the investor. That structure does not work at all for THC Therapeutics. When a company does that, it makes a statement of what they believe their current stock price should be and that they’re willing to raise money at a significant discount to market. I am now in the process of returning 1.8 Million shares of my stock in THCT back into the company’s treasury. I am doing this to limit any dilution that can occur with this offering. I’d be happy to personally answer any questions regarding this private placement. Please call or email me directly at Brandon@thctherapeutics.com. I would like to thank everyone for believing in my vision and I promise to do whatever it takes to make THC Therapeutics a premier Health and Healing Cannabis company.”

About THC Therapeutics:

THC Therapeutics is a forward-thinking publicly traded health and healing company in the cannabis industry that has "Better Health through the Science of Nature" as their mission statement. The company is dedicated to innovating new methods and refining current industry standards in the cannabis market. THC Therapeutics' plans for future growth include cultivation, dispensing, extractions, edibles, personal wellness centers and flotation therapy. For more information, visit THCTherapeutics.com.

Forward-Looking Statements Disclosure:

This press release may contain "forward-looking statements" within the meaning of the federal securities laws. In this context, forward-looking statements may address the Company's expected future business and financial performance, and often contain words such as "anticipates," "beliefs," "estimates," "expects," "intends," "plans," "seeks," "will," and other terms with similar meaning. These forward-looking statements by their nature address matters that are, to different degrees, uncertain. Although the Company believes that the assumptions upon which its forward-looking statements based are reasonable, it can provide no assurances that these assumptions will prove to be correct. All forward-looking statements in this press release are expressly qualified by such cautionary statements, risk, and uncertainties, and by reference to the underlying assumptions.

Phone: 702.602.THCC (8422)

Follow Brandon Romanek on Twitter:

Twitter @BrandonRomanek

Follow THC Therapeutics on Facebook and Twitter:

Twitter @THCTherapeutics

Facebook @THCTherapies

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
20 Oct
VWS
Der er for tiden en del debat omkring øget prispres på vindmøllemarkedet - bl.a. som følge af at Sie..
77
20 Oct
PNDORA
  Jeg har gentagne gange analyseret Pandora. Læsere, som ønsker min analyse af Pandoras forretningsm..
59
18 Oct
EI
Til direktionen.     Se så at få fyret den uduelige person, som I har ansat som moderator. Vedkommen..
43
18 Oct
NOVO-B
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee votes 16 - 0 in favor of approval fo..
21
20 Oct
TEVA
Jeg deler spekulationerne omkring Kåres tiltrædelse dvs. den dårlige nyhedsstrøm er snart slut. Min ..
19
18 Oct
EI
Og til Moderator:     Du UNDERSTÅR dig i at fjerne dette indlæg uden at have forelagt det direktione..
17
18 Oct
PNDORA
Markedsværdi = DKK 64 milliarder   Pandora ejer 2,30 % af aktierne (som vi må antage ikke kommer i o..
14
16 Oct
OMXC25
Jeg har fuldstændig mistet enhver form for respekt for EU.   EU er i den grad blevet til en taberfor..
14
20 Oct
PNDORA
lugte af noget personligt mod alfinvest, vil jeg nu tillade mig at drage tvivl, både ved hans hensig..
13
20 Oct
PNDORA
Vanvittigt godt formuleret Peter. Det er næsten som at tage på universitetet og studere grønlandsk a..
13

G4S plc UK DK : Director/PDMR Shareholding

20/10/2017 14:16:01
20 October 2017 G4S plc ("the Company") PDMR transaction - Initial Notification The Company announces that it has received notification that on 18 October 2017 Peter Neden, Regional President UK&I, a person discharging managerial responsibility (a "PDMR") had paper share certificates held in his name dematerialised and transferred into joint ownership with Lisa Neden, a person clo..

Admiral Group PLC : Director/PDMR Shareholding

29/09/2017 14:53:59
NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM 1 Details of the person discharging managerial responsibilities (PDMR)/person closely associated with them (PCA) a) Name Annette Court 2 ..

Man Group PLC : Form 8.3 - [Clinigen Group plc]

29/09/2017 12:19:01
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Man Group Plc (b) Owner or controller..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Guess & Co. Corporation Announces First Annual Meeting of Shareholders
2
T-Mobile to Release Q3 2017 Earnings on October 23, 2017
3
Sequent Announces Two New Sequent Platform Versions
4
Simmons Reports Third Quarter 2017 Earnings
5
H.B. Fuller Poised for Global Growth with Acquisition of Royal Adhesives & Sealants

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
23 October 2017 01:34:46
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20171020.1 - EUROWEB7 - 2017-10-23 02:34:46 - 2017-10-23 01:34:46 - 1000 - Website: OKAY